Last reviewed · How we verify
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety of the combination of ponatinib and trametinib as well as the most appropriate dosages of the combination.
Details
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | COMPLETED |
| Enrolment | 12 |
| Start date | Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Feb 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Non Small Cell Lung Cancer
- KRAS Gene Mutation
Interventions
- Trametinib 0.5 mg
- Trametinib 1 MG
- Trametinib 1.5 MG
- Trametinib 2 mg
- Ponatinib 15 MG
- Ponatinib 30 MG
Countries
United States